Biocryst Company Profile
What is the competitive landscape for BIOCRYST
BIOCRYST has three approved drugs.
There are eighteen US patents protecting BIOCRYST drugs.
Summary for Biocryst
| US Patents: | 18 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 3 |
Drugs and US Patents for Biocryst
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst | ORLADEYO | berotralstat dihydrochloride | PELLETS;ORAL | 219776-001 | Dec 11, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Biocryst | ORLADEYO | berotralstat dihydrochloride | PELLETS;ORAL | 219776-004 | Dec 11, 2025 | RX | Yes | Yes | 12,545,647*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Biocryst | ORLADEYO | berotralstat dihydrochloride | CAPSULE;ORAL | 214094-002 | Dec 3, 2020 | RX | Yes | Yes | 12,545,647*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Biocryst
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | 6,503,745 | ⤷ Start Trial |
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | 6,562,861 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Biocryst Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2023181543 | ⤷ Start Trial |
| Cyprus | 1123810 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2015134998 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Biocryst Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3113772 | 42/2021 | Austria | ⤷ Start Trial | PRODUCT NAME: BEROTRALSTAT UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/21/1544 20210504 |
| 3113772 | 202140032 | Slovenia | ⤷ Start Trial | PRODUCT NAME: BEROTRALSTAT AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; NATIONAL AUTHORISATION NUMBER: EU/1/21/1544; DATE OF NATIONAL AUTHORISATION: 20210430; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 3113772 | PA2021524 | Lithuania | ⤷ Start Trial | PRODUCT NAME: BEROTRALSTATAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS ; REGISTRATION NO/DATE: EU/1/21/1544 20210430 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
